Immunome Inc. 4

Isaac Barchas reported Rule 10b5-1 plan-driven sales of a total of 83,464 shares of Immunome Inc. common stock over August 10–12, 2026, for proceeds of about $2.18 million, leaving 92,211 shares owned directly.

On August 10, 11, and 12, 2026, reporting person Isaac Barchas, in his capacity tied to ABHMC II LLC and directly, reported open-market sales of Immunome Inc. common stock pursuant to pre-arranged Rule 10b5-1 trading plans. On August 10, 10,125 shares were sold at a weighted average price of approximately $26.07 per share, leaving 62,291 shares held indirectly through ABHMC II LLC, for which Barchas disclaims beneficial ownership beyond any pecuniary interest. On August 11, 62,291 indirectly held shares were sold at a weighted average price of approximately $26.23 per share, reducing indirect ownership to zero. On August 12, he sold 11,048 shares held directly at an average price of approximately $27.25 per share, resulting in direct ownership of 92,211 Immunome shares after the transaction. Across all three days, the reported sales totaled 83,464 shares, with an aggregate value of roughly $2.18 million using the disclosed average prices.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0001808343-26-000010

Alert Tier

7